Human umbilical cord mesenchymal stem cell injection cryopreservation liquid with high multiplication capacity

A technology of proliferative ability and quality stem cells, applied in the field of cell biology, can solve the problems of reduced cell proliferation ability and short cell viability maintenance time, and achieve high survival rate, reduced risk, and reduced content

CN112841175APending Publication Date: 2021-05-28朱灏
6 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2021-05-28

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a human umbilical cord mesenchymal stem cell injection cryopreservation solution with high multiplication capacity, which is prepared from the following raw materials in parts by volume: 1 to 5 parts of DMSO, 45 to 55 parts of compound electrolyte injection, 5 to 15 parts of dextran 40 glucose injection, 1 to 10 parts of sodium chloride injection, 1 to 10 parts of glucose injection, 20 to 40 parts of human serum albumin, and 3 to 6 parts of a serum substitute. The invention further discloses a preparation and cryopreservation method of the human umbilical cord mesenchymal stem cells, the content of DMOS is reduced, so that the clinical use risk is reduced, the human umbilical cord mesenchymal stem cells still keep a good cryopreservation effect, the human umbilical cord mesenchymal stem cells have high survival rate after cryopreservation and resuscitation, and meanwhile, the high value-added ability is kept. The proliferation capacity of unfrozen and resuscitated cells after 6 months of cryopreservation in the refrigerating fluid is equivalent to the proliferation capacity of fresh cells, and is far higher than the proliferation capacity of unfrozen and resuscitated cells after 6 months of cryopreservation in traditional refrigerating fluid.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of cell biology, and in particular relates to a cryopreserved solution of human umbilical cord mesenchymal stem cell injection with high proliferation ability. Background technique

[0002] Stem cells are a type of cells with self-renewal and multi-directional differentiation capabilities. The use of stem cells to treat various serious and intractable diseases has become a research hotspot at home and abroad. In addition to the characteristics of general stem cells, mesenchymal stem cells also have low immunogenicity and immunoregulatory effects. Therefore, this kind of cells has a very broad prospect in clinical application. Compared with other sources of mesenchymal stem cells, human umbilical cord mesenchymal stem cells have the advantages of sufficient source, non-invasiveness, strong proliferation ability, and no ethical issues in their acquisition, so they have become the most potential source of ther...

Examples

preparation example Construction

[0036] The second aspect of the present invention provides a method for preparing a cryopreserved solution of human umbilical cord mesenchymal stem cell injection with high proliferative capacity, comprising the following steps:

[0037]S1. According to the formula, draw DMSO and add it to the 500mL receiver, then slowly add compound electrolyte injection, dextran 40 glucose injection, sodium chloride injection, glucose injection, serum substitute to it, and shake while adding until mixed;

[0038] S2. Then slowly add the formula amount of human serum albumin, and mix up and down to obtain the cryopreserved solution of the human umbilical cord mesenchymal stem cell injection.

[0039] The method also solves the phenomenon of protein precipitation of human albumin in contact with DMSO.

[0040] In order to reduce the damage caused by DMSO in the freezing solution to cells in a normal temperature environment, in some preferred embodiments, the preparation method of the cryopres...

Embodiment 1

[0051] Example 1 provides a high-proliferation human umbilical cord mesenchymal stem cell injection cryopreservation solution, in parts by volume, its preparation raw materials include 4 parts of DMSO, 50 parts of compound electrolyte injection, and 40 parts of dextran and glucose injection. 10 parts, 5 parts of sodium chloride injection, 5 parts of glucose injection, 30 parts of human albumin, and 5 parts of serum substitute.

[0052] The DMSO is clinical grade DMSO, purchased from WAK-Chemie;

[0053] The compound electrolyte injection was purchased from Hebei Tiancheng Pharmaceutical Co., Ltd.;

[0054] The dextran 40 glucose injection was purchased from Sichuan Kelun Pharmaceutical Co., Ltd.;

[0055] The glucose injection was purchased from Jimin Health Management Co., Ltd.;

[0056] The sodium chloride injection was purchased from Guangdong Otsuka Pharmaceutical Co., Ltd.;

[0057] Described human serum albumin was purchased from Okte Fama AB Company;

[0058] The se...

Embodiment 2

[0067] Example 2 provides a cryopreserved solution of human umbilical cord mesenchymal stem cell injection with high proliferative capacity. By volume, its preparation raw materials include 4 parts of DMSO, 45 parts of compound electrolyte injection, and 40 parts of dextran and glucose injection. 10 parts, 5 parts of sodium chloride injection, 5 parts of glucose injection, 30 parts of human albumin, and 5 parts of serum substitute.

[0068] The DMSO is clinical grade DMSO, purchased from WAK-Chemie;

[0069] The compound electrolyte injection was purchased from Hebei Tiancheng Pharmaceutical Co., Ltd.;

[0070] The dextran 40 glucose injection was purchased from Sichuan Kelun Pharmaceutical Co., Ltd.;

[0071] The glucose injection was purchased from Jimin Health Management Co., Ltd.;

[0072] The sodium chloride injection was purchased from Guangdong Otsuka Pharmaceutical Co., Ltd.

[0073] The serum substitute was purchased from Beijing Dakewe Biotechnology Co., Ltd.

[...